Immunohistochemical examination dMM differential diagnosis is the most commonly used method diagnosis. However, there is no antibody which of mesothelioma cancer or totally specific, most common cancer there are only Antibodies response. Diagnosis of mesothelioma is built on the basis of negative reaction. Regular combination of several antibodies to reduce the false negative rate. And in recent years has been between the skin-associated antigen, or low specificity, sensitivity or poor, or only to frozen section, it is not widely used. Immunohistochemistry used in the following areas:
E-4.1 malignant mesothelioma cancer and the identification of brown, such as 5 〔〕 study found that the distinction between E-mesothelioma cancer and the best two markers for cEA and b72.3. At the same time positive for adenocarcinoma of the specificity of 100%, sensitivity 88%; at the same time on the negative mesothelioma specificity 99%, 97% sensitivity. cEA, b72.3 and leu-M1 will enable the combined 74% of the cases have been diagnosed. 6, Key ordonez〕 study cEA, leu-M1, b72.3 is the best marker, and ber-EP4 together will enable the application of more than 90% of mesothelioma cancer and a clear diagnosis. riera such as the application of heat 〔〕 7 antigen retrieval methods used antibodies to the re-evaluation found that most of the antibody in the heat after the repair of antigen to increase its sensitivity, and reduce non-specific. And found cEA, bg8 and ber-EP4 for the distinction between E-mesothelioma and adenocarcinoma of the best markers. Three combinations, the order of application, almost all of mesothelioma cancer with the right to distinguish between. Mesothelial-associated antigen hBME-1, thrombom odulin and calretinin sensitivity and specificity of these antibodies than low. However, antibodies and the combination of the above contribute to the diagnosis of mesothelioma.
E-4.2 malignant mesothelioma and adenocarcinoma with the reaction of mesothelial hyperplasia identification of benign and malignant mesothelium cell in the differential diagnosis of pathology is a difficult diagnosis. eMA and p53 〔〕 8 in benign and malignant mesothelium cell differential diagnosis of a certain value. 9 〔〕 wolanski such as the use of thymus membrane biopsy specimens, found in the eMA positive rate of malignant lesions in 73%, and benign lesions in 1 case of non-positive. The cEA, eMA and b72.3 joint application for the distinction between skin cancer and benign hyperplasia of the useful markers. b72.3 in breast cancer, lung cancer, ovarian cancer in the fluid were positive, healthy and free fluid in 1 case of positive 〔〕 10.
4.3 sarcomatoid sarcoma and mesothelioma, the limitations of fibroids and reactive fibrosis serous sarcomatoid mesothelioma differential expression of low-molecular-weight keratin, sarcoma, fibroma and the limitations of the reactive fibrosis serositis did not express any form of angle Protein. With broad-spectrum keratin marker aE1 / aE3 and low-molecular-weight keratin cAM5.2 can sarcomatoid mesothelioma and the limitations of fibroids, desmoid tumor-like mesothelioma and reactive fibrosis distinction between serous. 〔〕 11, and other montag study found 30 cases of sarcomatoid and mixed mesothelioma sarcoma-like areas on both aE1 / aE3 there is response, and 10 types of organizations, 39 spindle cell tumor and tumor-like process were negative, only A small number of spindle cell tumors, such as synovial sarcoma, epithelioid sarcoma, sarcoma carcinoma, sarcoma cancer occasionally positive. Mesothelial-associated antigen (hBME-1, thrombo-modulin, calretinin) in sarcomatoid mesothelioma in the negative, like mesothelioma sarcoma in the differential diagnosis of no value